Natera Announces Completion of Enrollment To the Randomized, Phase III ALTAIR Trial Of Signatera In Colorectal Cancer
Portfolio Pulse from Happy Mohamed
Natera, Inc. (NASDAQ:NTRA) has completed enrollment for the phase III ALTAIR clinical trial, which is evaluating the utility of the Signatera molecular residual disease (MRD) test in patients with stage II-IV resectable colorectal cancer (CRC). The trial is part of the CIRCULATE-Japan adaptive trial platform. The company expects to share primary results from ALTAIR in mid-2024.
July 28, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Natera's completion of enrollment for the ALTAIR trial is a significant milestone in the development of the Signatera MRD test for CRC patients. The results, expected in mid-2024, could potentially impact the company's stock positively if they are favorable.
The completion of enrollment for the ALTAIR trial is a key step in the development of Natera's Signatera MRD test. If the results, expected in mid-2024, are favorable, they could potentially lead to regulatory approval and commercialization of the test, which would likely have a positive impact on Natera's stock. However, as the results are not expected until 2024, the immediate impact on the stock is likely to be neutral.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100